How is Ephedra Legal?
On April 14th 2005 a Utah state court judge declared the current FDA control of Ephedra (Ma Huang) as a drug is wrong. The FDA has a limited amount of time in which to file an appeal to the ruling. If the appeal is filed, and granted, the FDA could propose a restriction and/or limitation on the sale of Ephedra. One thing is for sure, the FDA will not be able to write there own restrictions, as done before. They would have to present a proposal that would then be voted on through the house and senate.
As it stands, the future availability of ephedra in the United States is unknown. The FDA did make a brief statement stating that they would allow the sale of 10mg or less of Ephedra alkaloids per capsule. This would be only a recommendation because currently, the FDA has no legal control over the herb.
Industry Studies on Ephedra
In December of 2000, the council on Responsible Nutrition in connection with Cantox Health Sciences International, published a report entitled "Safety Assessment and Determination of a Tolerable Upper Limit For Ephedra" (Cantox Report). The Cantox Report reviewed nine randomized, double blind, placebo controlled studies each of which were at least of eight weeks in duration. Each of the studies monitored heart rate, blood pressure, adverse events, and other related tolerability parameters. In particular, one study revealed that cardiac arrythmias did not occur in subjects given 90 milligrams of ephedrine alkaloids per day verses placebo. The Cantox Report determined that the "lowest observed adverse effect level" is 150 milligrams of ephedrine alkaloids per day. Thus, the lowest observed adverse effect level is 50% higher than the maximum daily dose of ephedrine alkaloids recommended by the dietary supplement industry which is 100mg per day.
The Harvard/Columbia Study: Herbal Ephedra/Caffiene for Weight Loss: A Six Month Safety and Efficacy Trial.
This study examined the long-term safety and efficacy for weight loss of an herbal supplement containing Ma Huang and Kola Nut (30mg ephedrine alkaloids, three times per day). It was a six month randomized, double-blind placebo controlled trial, the results of which were published in the May 2002 issue of the International Journal of Obesity. After six months, "the tested product produces no adverse events and minimal side effects that are consistant with the known mechanism and action of Ephedrine and caffiene".
|